Firefly Bio’s Post

The launch of Fierfly Bio and the high science of degrader antibody conjugates.

We have a GREAT meeting planned for TOMORROW at Fairfield Dolan - Fairfield University Charles F. Dolan School of Business. LambdaVision, Inc., Nimbus Power Systems, Coegil, WAVE Drowning Prevention Systems, and CellsBin will present to Angel Investor Forum; and all companies are from CT!! We also have an educational presentation on our Fund V. Start time is 10:00AM. To learn more about the presenting companies, see below: WAVE Drowning Prevention Systems (CT Company) - Drowning prevention system with a reliable, simple, and low-cost necessary for widespread adoption in a market with multibillion dollar potential. LambdaVision, Inc. (CT Company) - Protein-based retinal implant to treat millions of patients affected by macular degeneration and retinitis pigmentosa. Nimbus Power Systems (CT Company) - Commercializing the world's most advanced, zero-emission, heavy-duty, fuel cell engine to replace diesel engines and eliminate emissions globally. Coegil (CT Company) - AI platform that helps small enterprises instantly find actionable insights and customized recommendations they need to make great decisions. CellsBin (CT Company) - CellsBin redefines the field of cell-analysis making is possible to analyze massive cell populations at microscopic precision.

This illustration tells you: 1) why Biocytogen is the first and most dominant drug target humanized mice (BioMice) provider; 2) why BioMice usage has been widely accepted only in recent several years.

🐭 The Power of #CRISPR and BioMice🐭 I believe in the power of BioMice models. These tools are game-changers in drug discovery, and I’m passionate about sharing them with you. Thanks to James Jin, Biocytogen VP, for the insights that fuel our work. 🐭Let’s push boundaries together!🐭

We have a GREAT meeting planned for 6/11at Fairfield Dolan - Fairfield University Charles F. Dolan School of Business. LambdaVision, Inc., Nimbus Power Systems, Coegil, WAVE Drowning Prevention Systems, and CellsBin will present to Angel Investor Forum; and all companies are from CT!! We also have an educational presentation on our Fund V. Start time is 10:00AM. To learn more about the presenting companies, see below: WAVE Drowning Prevention Systems (CT Company) - Drowning prevention system with a reliable, simple, and low-cost necessary for widespread adoption in a market with multibillion dollar potential. LambdaVision, Inc. (CT Company) - Protein-based retinal implant to treat millions of patients affected by macular degeneration and retinitis pigmentosa. Nimbus Power Systems (CT Company) - Commercializing the world's most advanced, zero-emission, heavy-duty, fuel cell engine to replace diesel engines and eliminate emissions globally. Coegil (CT Company) - AI platform that helps small enterprises instantly find actionable insights and customized recommendations they need to make great decisions. CellsBin (CT Company) - CellsBin redefines the field of cell-analysis making is possible to analyze massive cell populations at microscopic precision.

Ever find yourself stuck in the endless loop of colony counting? Well, it's time for a change! Watch this video, where my colleague Magnus Madsen explains how it’s done with Reshape imaging platform. One of the benefits that I would like to highlight is, that it is possible to simply perform end-point counts, allowing you to obtain accurate results quickly and easily.

How are Camena Bioscience addressing the long-standing challenges of throughput, scale and accuracy in #DNA synthesis? Read this latest SelectScience® case study to learn how the team have combined their TdT-free enzyme-based gSynth® platform with our #liquidhandling technology to reshape the field of DNA synthesis. Plus, discover the advantages this offers in applications such as multiplexed #CRISPR editing and #drugdiscovery. https://lnkd.in/guV4Khh7

We have come a long way and it feels like we’re only getting started! Learn more about today's news and Healx's approach to transforming the lives of #raredisease patients by using #AI in this BiotechTV feature below: https://lnkd.in/eV8hUdg4

THE MOST RESILIENT of #founders out there? This one in #biotech using #AI for #drugsiscovery. Meet Tim Guilliams and team have learned to harness resilience tools both mental, physiological and medical to maintain health in body and mind and team when facing extremes. The mission is not over for @healx but this a bacon of hope for the biotech startup ecosystem. Together with LabGenius and their round of late the promise is coming back to life. I had the pleasure of spending time with biotech legend Dr. Peter Pack one of the godfathers of monoclonal antibody discovery. Biotech is HARD, both because iterations are limited by the speed of biology, not the speed of light or commits to GitHub, and because of the limited funding paths / exit prospects. Biotech is in a dire state at the minute. Even UK biotech that plays in the big leagues of the drug discovery world despite the small population and relatively lean imvestment made here. Peter got me thinking about how hard being a biotech or techbio firm is at the best of time. Today is almost as low as 2002. We have many companies struggling to be funded despite some of them being proper ground breaking platforms for new approaches to treating and delaying disease and decline. Rt. Hon. Wes Streeting MP and then new government would do well to support investors in UK Biotech and lose the lead to liquidators or the US. WellFounded

Thinking outside the box